XML 148 R79.htm IDEA: XBRL DOCUMENT
v3.23.1

Segmentation of key figures - Top 20 (Details 9) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 50,545 | $ 51,626 | $ 48,659
US |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 17,653 | 16,818 | 16,484
Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 41,296 | 41,995 | 39,013
Innovative Medicines | Top 20 products [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 32,137 | 32,664 | 29,916
Innovative Medicines | Rest of portfolio [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 9,159 | 9,331 | 9,097
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 4,644 | 3,548 | 2,497
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 4,788 | 4,718 | 3,995
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,365 | 1,428 | 1,251
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,133 | 1,059 | 873
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,013 | 2,787 | 3,003
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,370 | 1,351 | 920
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,092 |  |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,770 | 1,693 | 1,542
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,231 | 937 | 687
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  |  | 635
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,088 | 2,016 | 1,738
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,923 | 2,060 | 1,958
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,561 | 1,595 | 1,339
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  | 587 |
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,874 | 2,160 | 1,933
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  | 584 |
Innovative Medicines | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 536 |  |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,238 | 1,413 | 1,439
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 859 | 1,092 | 1,199
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 745 | 1,024 | 1,188
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 743 | 901 | 980
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 652 | 773 | 1,003
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 512 | 938 | 1,083
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  |  | 653
Innovative Medicines | US |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 15,899 | 14,999 | 14,342
Innovative Medicines | US | Top 20 products [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 12,753 | 11,688 | 11,126
Innovative Medicines | US | Rest of portfolio [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 3,146 | 3,311 | 3,216
Innovative Medicines | US | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,354 | 1,712 | 1,277
Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,770 | 2,883 | 2,516
Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 570 | 501 | 400
Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,153 | 1,427 | 1,562
Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 434 | 469 | 459
Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 921 |  |
Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 678 | 606 | 569
Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 472 | 339 | 318
Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  |  | 259
Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,083 | 947 | 833
Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 877 | 882 | 859
Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  | 230 |
Innovative Medicines | US | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 196 |  |
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 800 | 843 | 837
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 205 | 263 | 315
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 14 | 14 | 16
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 55 | 51 | 124
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 171 | 521 | 644
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  |  | 138
Innovative Medicines | Rest of the world [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 25,397 | 26,996 | 24,671
Innovative Medicines | Rest of the world [member] | Top 20 products [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 19,384 | 20,976 | 18,790
Innovative Medicines | Rest of the world [member] | Rest of portfolio [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 6,013 | 6,020 | 5,881
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,290 | 1,836 | 1,220
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,018 | 1,835 | 1,479
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,365 | 1,428 | 1,251
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 563 | 558 | 473
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 860 | 1,360 | 1,441
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 936 | 882 | 461
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 171 |  |
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,092 | 1,087 | 973
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 759 | 598 | 369
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  |  | 376
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,005 | 1,069 | 905
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,046 | 1,178 | 1,099
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,561 | 1,595 | 1,339
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  | 357 |
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,874 | 2,160 | 1,933
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  | 584 |
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 340 |  |
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 438 | 570 | 602
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 859 | 1,092 | 1,199
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 540 | 761 | 873
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 729 | 887 | 964
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 597 | 722 | 879
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 341 | 417 | 439
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties |  |  | 515
Operating segments [member] | Innovative Medicines | Promoted Brands [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 31,396 | 29,754 | 25,319
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 4,756 | 3,560 | 2,497
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 4,644 | 3,548 | 2,497
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 7,287 | 7,205 | 6,119
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 4,788 | 4,718 | 3,995
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,365 | 1,428 | 1,251
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,133 | 1,059 | 873
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 5,051 | 5,007 | 4,272
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,013 | 2,787 | 3,003
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,370 | 1,351 | 920
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,092 | 372 | 15
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 4,723 | 4,101 | 3,666
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,770 | 1,693 | 1,542
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,231 | 937 | 687
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 474 | 577 | 635
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 6,452 | 6,430 | 5,617
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 2,088 | 2,016 | 1,738
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,923 | 2,060 | 1,958
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,561 | 1,595 | 1,339
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 536 | 587 | 474
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 194 | 164 | 105
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 3,127 | 3,451 | 3,148
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,874 | 2,160 | 1,933
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 479 | 584 | 623
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 9,900 | 12,241 | 13,694
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 1,238 | 1,413 | 1,439
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 859 | 1,092 | 1,199
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 745 | 1,024 | 1,188
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 743 | 901 | 980
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 652 | 773 | 1,003
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 512 | 938 | 1,083
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 323 | 563 | 653
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Zortress/Certican [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 329 | 431 | 452
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Neoral/Sandimmun(e) [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | 310 | 368 | 393
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Voltaren/Cataflam [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 334 | $ 373 | $ 360

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_ProductPortfolioAxis=nvs_Top20ProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BrandsAxis=nvs_PromotedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XolairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BrandsAxis=nvs_EstablishedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |